RU2482189C2 - Полипептиды е2 папилломавируса, применяемые для вакцинации - Google Patents
Полипептиды е2 папилломавируса, применяемые для вакцинации Download PDFInfo
- Publication number
- RU2482189C2 RU2482189C2 RU2009130791/10A RU2009130791A RU2482189C2 RU 2482189 C2 RU2482189 C2 RU 2482189C2 RU 2009130791/10 A RU2009130791/10 A RU 2009130791/10A RU 2009130791 A RU2009130791 A RU 2009130791A RU 2482189 C2 RU2482189 C2 RU 2482189C2
- Authority
- RU
- Russia
- Prior art keywords
- hpv
- polypeptide
- nucleic acid
- acid molecule
- molecule encoding
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 280
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 269
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 260
- 241001631646 Papillomaviridae Species 0.000 title claims abstract description 113
- 238000002255 vaccination Methods 0.000 title description 4
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 186
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 186
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 186
- 208000015181 infectious disease Diseases 0.000 claims abstract description 78
- 239000002245 particle Substances 0.000 claims abstract description 62
- 230000003612 virological effect Effects 0.000 claims abstract description 62
- 230000002458 infectious effect Effects 0.000 claims abstract description 54
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 46
- 239000002773 nucleotide Substances 0.000 claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 239000013604 expression vector Substances 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000013598 vector Substances 0.000 claims description 118
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 claims description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 46
- 241000341655 Human papillomavirus type 16 Species 0.000 claims description 43
- 239000012528 membrane Substances 0.000 claims description 36
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 28
- 101000622327 Human papillomavirus type 18 Regulatory protein E2 Proteins 0.000 claims description 27
- 101000954454 Human papillomavirus type 16 Replication protein E1 Proteins 0.000 claims description 25
- 230000002950 deficient Effects 0.000 claims description 23
- 230000010076 replication Effects 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 19
- 230000002085 persistent effect Effects 0.000 claims description 19
- 238000012217 deletion Methods 0.000 claims description 18
- 230000037430 deletion Effects 0.000 claims description 18
- 101000775744 Human papillomavirus type 18 Replication protein E1 Proteins 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 17
- 241000700618 Vaccinia virus Species 0.000 claims description 15
- 230000005860 defense response to virus Effects 0.000 claims description 15
- 108700038832 HPV-33 E2 Proteins 0.000 claims description 14
- 239000013603 viral vector Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 claims description 9
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 9
- 230000003248 secreting effect Effects 0.000 claims description 9
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 8
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 241000712079 Measles morbillivirus Species 0.000 claims description 6
- 208000021145 human papilloma virus infection Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 230000003442 weekly effect Effects 0.000 claims description 5
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 201000006082 Chickenpox Diseases 0.000 claims description 2
- 208000000666 Fowlpox Diseases 0.000 claims description 2
- 101000954519 Human papillomavirus type 18 Protein E6 Proteins 0.000 claims description 2
- 101000767629 Human papillomavirus type 18 Protein E7 Proteins 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 206010046980 Varicella Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 78
- 241000701806 Human papillomavirus Species 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 41
- 206010072219 Mevalonic aciduria Diseases 0.000 description 40
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 38
- 238000000034 method Methods 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 34
- 210000004379 membrane Anatomy 0.000 description 32
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 24
- 230000004048 modification Effects 0.000 description 24
- 238000012986 modification Methods 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 23
- 108020004705 Codon Proteins 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- 241000701646 Kappapapillomavirus 2 Species 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 17
- 230000003902 lesion Effects 0.000 description 17
- 230000006378 damage Effects 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 230000035772 mutation Effects 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 239000013543 active substance Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 231100001222 nononcogenic Toxicity 0.000 description 11
- 230000000295 complement effect Effects 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 238000004873 anchoring Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 238000002744 homologous recombination Methods 0.000 description 8
- 230000006801 homologous recombination Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 238000002741 site-directed mutagenesis Methods 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- -1 genomic DNA Substances 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101150082674 E2 gene Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000009826 neoplastic cell growth Effects 0.000 description 5
- 208000003154 papilloma Diseases 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 101150029662 E1 gene Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101100102460 Human papillomavirus type 16 E2 gene Proteins 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 102220543674 Protein patched homolog 2_E39A_mutation Human genes 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000010307 cell transformation Effects 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 230000002246 oncogenic effect Effects 0.000 description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000701828 Human papillomavirus type 11 Species 0.000 description 3
- 101100450563 Mus musculus Serpind1 gene Proteins 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 230000009088 enzymatic function Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 238000009595 pap smear Methods 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000006490 viral transcription Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010051999 Anogenital dysplasia Diseases 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 108700023463 Bovine papillomavirus E2 Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 2
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 101100540286 Human papillomavirus type 16 E1 gene Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000002573 colposcopy Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 101150106093 gpt gene Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- ITFICYZHWXDVMU-IPTZIORSSA-N (2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-amino-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-oxopentanoyl]amino]pentanedioic acid Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(=O)O)N ITFICYZHWXDVMU-IPTZIORSSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- LBVBUKNMHPIEHN-UHFFFAOYSA-N 4-amino-1,3-dihydroimidazo[4,5-c]quinolin-2-one Chemical class NC1=NC2=CC=CC=C2C2=C1NC(=O)N2 LBVBUKNMHPIEHN-UHFFFAOYSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 101100272719 Arabidopsis thaliana BRG3 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 101710202081 FAD-linked sulfhydryl oxidase Proteins 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 101000926057 Human herpesvirus 2 (strain G) Envelope glycoprotein C Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100348738 Mus musculus Noc3l gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 101710112477 Phycobiliprotein ApcE Proteins 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710132593 Protein E2 Proteins 0.000 description 1
- 102220543672 Protein patched homolog 2_E43A_mutation Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101800000874 Small capsid protein Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101150029803 TMP gene Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000018777 Vulvar intraepithelial neoplasia Diseases 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 101100514842 Xenopus laevis mtus1 gene Proteins 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940124866 human papillomavirus vaccine Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000016412 positive regulation of cytokine production Effects 0.000 description 1
- 230000020073 positive regulation of transport Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108010059128 rabies virus glycoprotein peptide Proteins 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000018024 regulation of viral transcription Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102220285342 rs777971423 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360004.1 | 2007-01-30 | ||
| EP07360004 | 2007-01-30 | ||
| EP07360018.1 | 2007-05-15 | ||
| EP07360018 | 2007-05-15 | ||
| PCT/EP2008/051032 WO2008092854A2 (en) | 2007-01-30 | 2008-01-29 | Papillomavirus e2 polypeptide used for vaccination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013102035/10A Division RU2013102035A (ru) | 2007-01-30 | 2013-01-17 | Полипептиды е2 папилломавируса, применяемые для вакцинации |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009130791A RU2009130791A (ru) | 2011-03-10 |
| RU2482189C2 true RU2482189C2 (ru) | 2013-05-20 |
Family
ID=39399907
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009130791/10A RU2482189C2 (ru) | 2007-01-30 | 2008-01-29 | Полипептиды е2 папилломавируса, применяемые для вакцинации |
| RU2013102035/10A RU2013102035A (ru) | 2007-01-30 | 2013-01-17 | Полипептиды е2 папилломавируса, применяемые для вакцинации |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013102035/10A RU2013102035A (ru) | 2007-01-30 | 2013-01-17 | Полипептиды е2 папилломавируса, применяемые для вакцинации |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8420103B2 (enExample) |
| EP (2) | EP2118292B1 (enExample) |
| JP (1) | JP5474567B2 (enExample) |
| KR (1) | KR101636575B1 (enExample) |
| CN (1) | CN101617052A (enExample) |
| AR (1) | AR065076A1 (enExample) |
| AT (1) | ATE518958T1 (enExample) |
| AU (1) | AU2008209759B2 (enExample) |
| BR (1) | BRPI0806350A2 (enExample) |
| CA (1) | CA2675355C (enExample) |
| CL (1) | CL2008000249A1 (enExample) |
| DK (1) | DK2118292T3 (enExample) |
| IL (2) | IL199939A (enExample) |
| MX (1) | MX2009008118A (enExample) |
| PE (1) | PE20081723A1 (enExample) |
| PL (1) | PL2118292T3 (enExample) |
| RU (2) | RU2482189C2 (enExample) |
| TW (1) | TW200840869A (enExample) |
| WO (1) | WO2008092854A2 (enExample) |
| ZA (1) | ZA200904932B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009012326A (es) * | 2007-05-15 | 2010-02-10 | Transgene Sa | Peptidos de señalizacion. |
| EP2162544B1 (en) * | 2007-05-15 | 2013-04-17 | Transgene SA | Vectors for multiple gene expression |
| KR102216962B1 (ko) * | 2011-10-12 | 2021-02-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법 |
| WO2014009433A1 (en) | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterium resuscitation promoting factor for use as adjuvant |
| US10232030B2 (en) * | 2013-03-12 | 2019-03-19 | Inovio Pharmaceuticals, Inc. | Vaccines for human papilloma virus and methods for using the same |
| WO2015149051A1 (en) * | 2014-03-28 | 2015-10-01 | The Johns Hopkins University | Treatment regimen using cancer vaccines and local adjuvants and their use |
| CN107075521B (zh) * | 2014-11-04 | 2021-06-08 | 扬森疫苗与预防公司 | 治疗性hpv16疫苗 |
| US10548930B2 (en) * | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
| CN109862939A (zh) * | 2016-06-03 | 2019-06-07 | 埃特彼塞斯公司 | 用于治疗人乳头瘤病毒(hpv)相关疾病的组合物和方法 |
| WO2018060288A1 (en) * | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| EP3461497A1 (en) | 2017-09-27 | 2019-04-03 | GlaxoSmithKline Biologicals S.A. | Viral antigens |
| US11012555B2 (en) * | 2017-11-20 | 2021-05-18 | International Business Machines Corporation | Non-verbal sensitive data authentication |
| KR102222582B1 (ko) * | 2018-02-02 | 2021-03-04 | 주식회사 에스엘백시젠 | 신규 다가 hpv 백신 조성물 |
| US12391746B2 (en) | 2018-02-20 | 2025-08-19 | Emory University | HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth |
| AU2019229653B2 (en) | 2018-03-07 | 2025-09-11 | Transgene | Parapoxvirus vectors |
| EP3891123A4 (en) | 2018-12-03 | 2022-12-14 | Board of Regents, The University of Texas System | ANALOGS OF OLIGO-BENZAMIDE AND THEIR USE IN THE TREATMENT OF CANCER |
| CN116200416B (zh) * | 2023-02-15 | 2024-03-12 | 北京康乐卫士生物技术股份有限公司 | 一种基于Tac启动子的质粒表达载体构建及其用途 |
| WO2025199501A1 (en) * | 2024-03-22 | 2025-09-25 | Gritstone Bio, Inc. | Human papillomavirus (hpv) vaccines |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992016636A1 (en) * | 1991-03-14 | 1992-10-01 | Cantab Pharmaceuticals Research Limited | Recombinant virus vectors encoding human papillomavirus proteins |
| WO1997046693A1 (fr) * | 1996-06-04 | 1997-12-11 | Pasteur Merieux Serums Et Vaccins | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| US20020028498A1 (en) * | 1998-11-30 | 2002-03-07 | Ledezma Ricardo R. | Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses |
| RU2206608C2 (ru) * | 1994-05-16 | 2003-06-20 | Мерк Энд Ко., Инк. | Папилломавирусные вакцины |
| WO2004031222A2 (en) * | 2002-10-03 | 2004-04-15 | Glaxo Group Limited | Dna vaccine encoding at least two nonstructural early proteins of papillomavirus |
| WO2005060993A1 (en) * | 2003-12-24 | 2005-07-07 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| WO1994012629A1 (en) * | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| WO1998000524A1 (fr) | 1996-07-01 | 1998-01-08 | Rhone-Poulenc Rorer S.A. | Procede de production d'adenovirus recombinants |
| EP1707631A3 (en) | 1996-11-20 | 2006-12-27 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| JP2001506126A (ja) | 1996-12-13 | 2001-05-15 | シェーリング コーポレイション | ウイルスの精製方法 |
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| WO1999014377A2 (en) | 1997-09-16 | 1999-03-25 | Innogenetics N.V. | Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization |
| FR2774699B1 (fr) * | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| AU779267B2 (en) | 1998-12-31 | 2005-01-13 | Centelion S.A.S. | Method for separating viral particles |
| DE60010654T2 (de) | 1999-02-04 | 2005-06-16 | Geron Corp., Menlo Park | Replikativer virus gesteuert von dem promotor der reversen telomerase transkriptase zur behandlung von krebs |
| ATE332364T1 (de) | 1999-02-22 | 2006-07-15 | Transgene Sa | Verfahren zur gewinnung von purifizierter virenzuammensetzung |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| AU772611B2 (en) | 1999-08-25 | 2004-05-06 | Merck Sharp & Dohme Corp. | Synthetic human papillomavirus genes |
| US7001596B1 (en) | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| US20020029498A1 (en) * | 2000-07-03 | 2002-03-14 | Howard Harrison | Rapid cool iron and related iron improvements |
| WO2002008435A1 (en) | 2000-07-21 | 2002-01-31 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
| AU2002344190B2 (en) | 2001-05-30 | 2007-10-18 | Transgene S.A. | Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| WO2003018055A1 (en) | 2001-08-23 | 2003-03-06 | Merck & Co., Inc. | Vaccine using papilloma virus e proteins delivered by viral vector |
| EA007811B1 (ru) * | 2002-05-16 | 2007-02-27 | Бавариан Нордик А/С | Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva) |
| WO2005089164A2 (en) | 2003-12-31 | 2005-09-29 | Pharmexa Inc. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
-
2008
- 2008-01-29 RU RU2009130791/10A patent/RU2482189C2/ru not_active IP Right Cessation
- 2008-01-29 KR KR1020097016704A patent/KR101636575B1/ko not_active Expired - Fee Related
- 2008-01-29 BR BRPI0806350-8A patent/BRPI0806350A2/pt not_active Application Discontinuation
- 2008-01-29 TW TW097103230A patent/TW200840869A/zh unknown
- 2008-01-29 AU AU2008209759A patent/AU2008209759B2/en not_active Ceased
- 2008-01-29 PE PE2008000212A patent/PE20081723A1/es not_active Application Discontinuation
- 2008-01-29 MX MX2009008118A patent/MX2009008118A/es active IP Right Grant
- 2008-01-29 AT AT08708349T patent/ATE518958T1/de not_active IP Right Cessation
- 2008-01-29 CN CN200880003650A patent/CN101617052A/zh active Pending
- 2008-01-29 WO PCT/EP2008/051032 patent/WO2008092854A2/en not_active Ceased
- 2008-01-29 AR ARP080100357A patent/AR065076A1/es not_active Application Discontinuation
- 2008-01-29 PL PL08708349T patent/PL2118292T3/pl unknown
- 2008-01-29 US US12/449,197 patent/US8420103B2/en not_active Expired - Fee Related
- 2008-01-29 JP JP2009547667A patent/JP5474567B2/ja not_active Expired - Fee Related
- 2008-01-29 EP EP08708349A patent/EP2118292B1/en not_active Not-in-force
- 2008-01-29 DK DK08708349.9T patent/DK2118292T3/da active
- 2008-01-29 CA CA2675355A patent/CA2675355C/en not_active Expired - Fee Related
- 2008-01-29 EP EP11175811A patent/EP2390340A3/en not_active Withdrawn
- 2008-01-29 CL CL200800249A patent/CL2008000249A1/es unknown
-
2009
- 2009-01-01 ZA ZA200904932A patent/ZA200904932B/xx unknown
- 2009-07-19 IL IL199939A patent/IL199939A/en active IP Right Grant
-
2011
- 2011-10-06 IL IL215599A patent/IL215599A/en not_active IP Right Cessation
-
2013
- 2013-01-17 RU RU2013102035/10A patent/RU2013102035A/ru unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992016636A1 (en) * | 1991-03-14 | 1992-10-01 | Cantab Pharmaceuticals Research Limited | Recombinant virus vectors encoding human papillomavirus proteins |
| RU2206608C2 (ru) * | 1994-05-16 | 2003-06-20 | Мерк Энд Ко., Инк. | Папилломавирусные вакцины |
| WO1997046693A1 (fr) * | 1996-06-04 | 1997-12-11 | Pasteur Merieux Serums Et Vaccins | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| US20020028498A1 (en) * | 1998-11-30 | 2002-03-07 | Ledezma Ricardo R. | Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses |
| WO2004031222A2 (en) * | 2002-10-03 | 2004-04-15 | Glaxo Group Limited | Dna vaccine encoding at least two nonstructural early proteins of papillomavirus |
| WO2005060993A1 (en) * | 2003-12-24 | 2005-07-07 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008209759A1 (en) | 2008-08-07 |
| RU2013102035A (ru) | 2014-07-27 |
| CL2008000249A1 (es) | 2008-05-30 |
| PE20081723A1 (es) | 2008-12-14 |
| RU2009130791A (ru) | 2011-03-10 |
| JP5474567B2 (ja) | 2014-04-16 |
| IL215599A (en) | 2014-11-30 |
| PL2118292T3 (pl) | 2011-12-30 |
| US20100143408A1 (en) | 2010-06-10 |
| EP2118292A2 (en) | 2009-11-18 |
| EP2390340A3 (en) | 2012-02-22 |
| US8420103B2 (en) | 2013-04-16 |
| IL199939A0 (en) | 2010-04-15 |
| TW200840869A (en) | 2008-10-16 |
| CA2675355A1 (en) | 2008-08-07 |
| AR065076A1 (es) | 2009-05-13 |
| MX2009008118A (es) | 2009-10-13 |
| WO2008092854A3 (en) | 2008-10-30 |
| JP2010516287A (ja) | 2010-05-20 |
| IL199939A (en) | 2013-02-28 |
| BRPI0806350A2 (pt) | 2011-09-06 |
| EP2118292B1 (en) | 2011-08-03 |
| AU2008209759B2 (en) | 2013-03-21 |
| ZA200904932B (en) | 2010-04-28 |
| CN101617052A (zh) | 2009-12-30 |
| ATE518958T1 (de) | 2011-08-15 |
| KR20090129399A (ko) | 2009-12-16 |
| KR101636575B1 (ko) | 2016-07-05 |
| CA2675355C (en) | 2015-04-28 |
| WO2008092854A2 (en) | 2008-08-07 |
| EP2390340A2 (en) | 2011-11-30 |
| IL215599A0 (en) | 2011-11-30 |
| DK2118292T3 (da) | 2011-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2482189C2 (ru) | Полипептиды е2 папилломавируса, применяемые для вакцинации | |
| US20100055069A1 (en) | Hpv-18-based papillomavirus vaccines | |
| US20100061957A1 (en) | Hpv-16-based papillomavirus vaccines | |
| RU2462513C2 (ru) | Векторы для множественной генной экспрессии | |
| ES2370674T3 (es) | Polipéptido e2 de papilomavirus utilizado para la vacunación. | |
| AU2013201033A1 (en) | Papillomavirus E2 Polypeptide Used for Vaccination | |
| WO2007121893A1 (en) | Method for treating hpv infected patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200130 |